Change is on its way in Washington, D.C. And the possible impacts for a big biotech like Gilead Sciences Let’s start with the potential negatives. Donald Trump has made it clear that he wants to allow Medicare to negotiate directly with drugmakers to secure lower prices for prescription drugs.